United Therapeutics Corp. is a pharmaceutical company based in the United States that focuses on drug development for pulmonary arterial hypertension, a rare and progressive disease. They specialize in therapies that target the prostacyclin pathway, with a primary focus on the molecule treprostinil. While also marketing a pediatric oncology drug, United Therapeutics primarily generates sales within the US. With an ESG score of 22.1, the company is deemed to be at a medium risk level.